Neovacs S.A Ret. on equity
What is the Ret. on equity of Neovacs S.A?
The Ret. on equity of Neovacs S.A. is -11.05%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on EURONEXT compared to Neovacs S.A
What does Neovacs S.A do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Companies with ret. on equity similar to Neovacs S.A
- SMA Solar Technology AG has Ret. on equity of -11.10%
- Alloy Resources has Ret. on equity of -11.09%
- Clean Fuels Corp has Ret. on equity of -11.09%
- ONE Hospitality Inc has Ret. on equity of -11.08%
- PetroNeft Resources plc has Ret. on equity of -11.07%
- PetroNeft Resources plc has Ret. on equity of -11.07%
- Neovacs S.A has Ret. on equity of -11.05%
- National has Ret. on equity of -11.04%
- The Local Shopping REIT PLC has Ret. on equity of -11.04%
- MSP Steel & Power has Ret. on equity of -11.03%
- AF2 Capital has Ret. on equity of -11.02%
- Great Boulder Resources has Ret. on equity of -11.02%
- CFOAM has Ret. on equity of -11.01%